CD274 and neoplasm: In addition to employing programmed death-ligand 1 (PD-L1) expression or tumor mutation burden (TMB) for predicting tumor response to ICT, recent research suggests that immunogenomic characteristics may decrease the abundance of TILs and contribute to primary resistance to ICT.6